uvepexatawus.blogspot.com
Government regulators granted accelerated approval for Avastinn for people with glioblastoma who have experiencerd a progression of the disease followinfgprior treatment. Glioblastoma affects 10,000p people per year nationwide. Glioblastoma tumors nearlgy always return followinginitial treatment. Dr. Lisa Fichtel, a medical oncologistg and hematologist with the START Center for Cancer Care in San says she has witnessed first hand how this drug has helper patients withbrain cancer.
“This is the firsr new treatment in more than 10 yearss for people with this type of aggressivebrain cancer,” Fichtel Fichtel sees at least one new brain cancer patient each week and has seen the positivs impact this drug has had in not only slowin g the progression of the disease but also improving the qualitg of life of patients in San Antonio. Genentech gainefd FDA approval after concludingan multicenter, non-comparative Phase II study of 167 patientds with glioblastoma.
The South San Francisco-based biotechnology company workato discover, develop, manufacture and commercializd medicines that treat patients with serious or life-threatening medical provides oncology research and treatment.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment